Detail Information of Genetic Polymorphisms
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0022 Transporter Info | ||||
| Gene Name | SLC15A2 | ||||
| Protein Name | Peptide transporter 2 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Genetic Polymorphisms of DT (GPD) | |||||
| Genetic Polymorphism | rs2257212 | ||||
| Site of GPD | chr3:121924957 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>G / C>T | ||||
| Minor Allele Frequency | T=0.4519/2263 (Global) | ||||
| Genotype CC | Click to Show/Hide the Full List of Affected Drugs: 3 Drugs in Total | ||||
| Sorafenib | Drug Info | Hepatocellular Carcinoma | Correlated with the decreased progression-free survival in patients (compare with Genotypes CT + TT) | [ 1] | |
| Sorafenib | N.A. | Progression-free Survival | Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT. | [ 1] | |
| Sorafenib | N.A. | Hepatocellular Carcinoma | Genotype CC is associated with decreased progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT. | [ 1] | |
| Allele T | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Colistimethate | N.A. | Nephrotoxicity | Allele T is associated with increased likelihood of nephrotoxicity when treated with colistimethate in people with Bacterial Infections as compared to allele C. | [ 2] | |
| Genotype CT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Sorafenib | N.A. | Hepatocellular Carcinoma | Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib. | [ 1] | |
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Sorafenib | N.A. | Hepatocellular Carcinoma | Patients with genotype TT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib. | [ 1] | |
| Genetic Polymorphism | rs1143671 | ||||
| Site of GPD | chr3:121928439 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | C>A / C>G / C>T | ||||
| Minor Allele Frequency | C=0.5510/1090 (Global) | ||||
| Genotype TT | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Warfarin | N.A. | Nephrotoxicity | Genotype TT is associated with decreased dose of warfarin as compared to genotype CC. | [ 3] | |
| Genetic Polymorphism | rs1143672 | ||||
| Site of GPD | chr3:121929321 (GRCh38.p12) | ||||
| GPD Type | SNP | ||||
| Allele(s) in dbSNP | G>A | ||||
| Minor Allele Frequency | G=0.5510/1090 (Global) | ||||
| Genotype AA | Click to Show/Hide the Full List of Affected Drugs: 1 Drugs in Total | ||||
| Warfarin | N.A. | Nephrotoxicity | Genotype AA is associated with decreased dose of warfarin as compared to genotype GG. | [ 3] | |
| References | |||||
| 1 | SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget. 2015 Jun 30;6(18):16449-60. | ||||
| 2 | Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity. Clin Transl Sci. 2024 Mar;17(3):e13764. | ||||
| 3 | Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.